262 related articles for article (PubMed ID: 29730587)
1. Neutropenia with fatal outcome in a multiple sclerosis patient 23 days after alemtuzumab infusion.
Yiannopoulou KG; Papadimitriou D; Anastasiou AI; Siakantaris M
Mult Scler Relat Disord; 2018 Jul; 23():15-16. PubMed ID: 29730587
[TBL] [Abstract][Full Text] [Related]
2. Disseminated necrotizing leukoencephalopathy eight months after alemtuzumab treatment for multiple sclerosis.
Metz I; Rieckmann P; Kallmann BA; Brück W
Acta Neuropathol Commun; 2016 Aug; 4(1):81. PubMed ID: 27503238
[No Abstract] [Full Text] [Related]
3. Mortality from Listeria monocytogenes meningoencephalitis following escalation to alemtuzumab therapy for relapsing-remitting Multiple Sclerosis.
Canham LJW; Manara A; Fawcett J; Rolinski M; Mortimer A; Inglis KEA; Cottrell DA
Mult Scler Relat Disord; 2018 Aug; 24():38-41. PubMed ID: 29885597
[TBL] [Abstract][Full Text] [Related]
4. Pneumonitis secondary to alemtuzumab in a patient with multiple sclerosis - A non-infectious cause of breathlessness.
Whiteside D; Barth S; Datta A; Trip SA
Mult Scler Relat Disord; 2018 May; 22():139-140. PubMed ID: 29684788
[TBL] [Abstract][Full Text] [Related]
5. Acute coronary syndrome associated with alemtuzumab infusion in multiple sclerosis.
Ferraro D; Camera V; Vitetta F; Zennaro M; Ciolli L; Nichelli PF; Sola P
Neurology; 2018 May; 90(18):852-854. PubMed ID: 29602915
[No Abstract] [Full Text] [Related]
6. A case of Alemtuzumab-induced neutropenia in multiple sclerosis in association with the expansion of large granular lymphocytes.
Vakrakou AG; Tzanetakos D; Valsami S; Grigoriou E; Psarra K; Tzartos J; Anagnostouli M; Andreadou E; Evangelopoulos ME; Koutsis G; Chrysovitsanou C; Gialafos E; Dimitrakopoulos A; Stefanis L; Kilidireas C
BMC Neurol; 2018 Oct; 18(1):178. PubMed ID: 30373566
[TBL] [Abstract][Full Text] [Related]
7. Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment.
Baker D; Giovannoni G; Schmierer K
Mult Scler Relat Disord; 2017 Nov; 18():181-183. PubMed ID: 29141806
[TBL] [Abstract][Full Text] [Related]
8. Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab.
Saarela M; Senthil K; Jones J; Tienari PJ; Soilu-Hänninen M; Airas L; Coles A; Saarinen JT
Neurology; 2018 May; 90(18):849-851. PubMed ID: 29602914
[No Abstract] [Full Text] [Related]
9. Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD).
Vukusic S; Brassat D; de Seze J; Izquierdo G; Lysandropoulos A; Moll W; Vanopdenbosch L; Arque MJ; Kertous M; Rufi P; Oreja-Guevara C
Mult Scler Relat Disord; 2019 Apr; 29():7-14. PubMed ID: 30654246
[TBL] [Abstract][Full Text] [Related]
10. Early neutropenia with thrombocytopenia following alemtuzumab treatment for multiple sclerosis: case report and review of literature.
Maniscalco GT; Cerillo I; Servillo G; Napolitano M; Guarcello G; Abate V; Improta G; Florio C
Clin Neurol Neurosurg; 2018 Dec; 175():134-136. PubMed ID: 30419425
[TBL] [Abstract][Full Text] [Related]
11. Alemtuzumab-induced red cell aplasia and other immune cytopenias: not so 'pure'.
Aitken L; Patel R; D'Rozario J; Choi P
Immunotherapy; 2022 Feb; 14(2):95-99. PubMed ID: 34743591
[TBL] [Abstract][Full Text] [Related]
12. Acute leukocytosis during alemtuzumab treatment in patients with active relapsing-remitting multiple sclerosis.
Iovino A; Aruta F; Carotenuto A; Manganelli F; Iodice R
Mult Scler Relat Disord; 2019 Feb; 28():98-100. PubMed ID: 30580038
[TBL] [Abstract][Full Text] [Related]
13. Early transient asymptomatic neutropenia associated with alemtuzumab treatment in multiple sclerosis: a case report.
Galgani S; Prosperini L; Haggiag S; Tortorella C; Gasperini C
J Neurol; 2018 Sep; 265(9):2152-2153. PubMed ID: 30019085
[No Abstract] [Full Text] [Related]
14. Recurrent and universal alopecia areata following alemtuzumab treatment in multiple sclerosis: A secondary autoimmune disease.
Alcalá C; Pzére-Miralles F; Gascón F; Evole M; Estutia M; Gil-Perotín S; Casanova B
Mult Scler Relat Disord; 2019 Jan; 27():406-408. PubMed ID: 30530069
[No Abstract] [Full Text] [Related]
15. Induction of disease remission with one cycle of alemtuzumab in relapsing-remitting MS.
Kocsik AS; Klein DE; Liedke M; Kaunzner UW; Nealon NM; Gauthier SA; Vartanian T; Perumal JS
J Neurol; 2018 May; 265(5):1226-1229. PubMed ID: 29666985
[TBL] [Abstract][Full Text] [Related]
16. Acute myocardial infarction associated with initial alemtuzumab infusion cycle in relapsing-remitting multiple sclerosis.
Romba MC; Newsome SD; McArthur JC
Mult Scler Relat Disord; 2019 Sep; 34():100-102. PubMed ID: 31252364
[TBL] [Abstract][Full Text] [Related]
17. Acute cardiotoxicity associated with alemtuzumab infusion for multiple sclerosis.
Ahrabian D; Neill L; Bell R; Leary SM
Mult Scler; 2020 May; 26(6):735-737. PubMed ID: 32298216
[TBL] [Abstract][Full Text] [Related]
18. Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis.
Holmøy T; Fevang B; Olsen DB; Spigset O; Bø L
BMC Res Notes; 2019 Aug; 12(1):497. PubMed ID: 31405369
[TBL] [Abstract][Full Text] [Related]
19. Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab.
Meunier B; Rico A; Seguier J; Boutiere C; Ebbo M; Harle JR; Schleinitz N; Pelletier J
Mult Scler; 2018 May; 24(6):811-813. PubMed ID: 29359614
[TBL] [Abstract][Full Text] [Related]
20. Pneumocystis pneumonia in a patient treated with alemtuzumab for relapsing multiple sclerosis.
Lau AY; Lui GCY; Chan KP; Au C; Mok VCT; Ziemssen T
Mult Scler Relat Disord; 2020 Feb; 38():101503. PubMed ID: 31743846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]